Spyre Therapeutics, Inc. (SYRE)

72.24 +3.62 (+5.27%) USD  |  NASDAQ  |  Apr 29, 10:29
More

Spyre Therapeutics Revenue Estimates for Current Fiscal Year

Revenue Estimates for Current Fiscal Year Chart

View Revenue Estimates for Current Fiscal Year for SYRE.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Revenue Estimates for Current Fiscal Year Chart
Start Trial

Historical Data

View Historical Data
Start Trial

Revenue Estimates for Current Fiscal Year Range, Past 5 Years

View Revenue Estimates for Current Fiscal Year Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Revenue Estimates for Current Fiscal Year Benchmarks

View Revenue Estimates for Current Fiscal Year Benchmarks
Start Trial
Tyra Biosciences, Inc. Upgrade
Replimune Group, Inc. Upgrade
Savara, Inc. Upgrade
Regeneron Pharmaceuticals, Inc. Upgrade
Agios Pharmaceuticals, Inc. Upgrade

Revenue Estimates for Current Fiscal Year Related Metrics

EPS Estimates for Current Quarter Upgrade
EPS Estimates for Next Quarter Upgrade
EPS Estimates for Current Fiscal Year Upgrade
EPS Estimates for Next Fiscal Year Upgrade